COMPARISON OF PROTEIN GLYCATION INHIBITORY AND TOXIC EFFECTS OF ACETYLSALICYLIC-ACID IN EXPERIMENTAL DIABETES

The main objective of the present investigation is to compare the effect of acetylsalicylic acid on glycation of serum proteins in diabetic rats and toxic effect of the applied drug on liver and kidney in non-diabetic rats. Fructosamine test was used for the evaluation of the inhibitory effect of acetylsalicylic acid on an enhanced glycosylation of serum proteins in diabetic rats. Toxic effects on kidney and liver were studied by measuring activities of alanine aminotransferase in serum, N-acetyl-beta-D-glucosaminidase in serum and urine as well as alanine aminopeptidase in urine. This scheme was applied because increased activities of enzymes were present in a poorly controlled diabetes. Inhibitory effect of acetylsalicylic acid on an enhanced protein glycation in diabetic rats was achieved after application of 400 mg kg-1 body mass per day. After 12 days of continuous treatment, only activities of N-acetyl-beta-D-glucosaminidase in urine of seven non-diabetic rats were increased indicating this enzyme to be a sensitive and predictive indicator of drug nephrotoxicity after a short period of treatment. No changes in alanine aminotransferase activities were detected, probably because hepatotoxic reactions can be produced as a cumulative phenomenon requiring more time to develop. Taking into account the observed drug induced damage on the gastric mucosa already after 12 days of treatment it is appropriate to assess the usage of microencapsulated drug in vivo.